Expand INKT Menu
INKT MENU

INKT Latest Press Releases

-- June 3, 2026 --

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting Globe Newswire 4:30 PM

-- May 28, 2026 --

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness Globe Newswire 9:04 AM

-- May 21, 2026 --

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 Business Wire 5:00 PM
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC Business Wire 5:00 PM

-- May 20, 2026 --

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications Globe Newswire 11:07 AM

-- May 15, 2026 --

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer Business Wire 4:11 PM
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation Globe Newswire 7:30 AM

-- May 14, 2026 --

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness Globe Newswire 7:30 AM

-- May 12, 2026 --

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 Globe Newswire 7:35 AM

-- May 11, 2026 --

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development Business Wire 8:45 AM

-- May 8, 2026 --

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs Globe Newswire 4:30 PM

-- April 17, 2026 --

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer Globe Newswire 3:00 PM

-- April 3, 2026 --

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 Globe Newswire 7:30 AM

-- April 2, 2026 --

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy Globe Newswire 7:30 AM

-- April 1, 2026 --

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference Globe Newswire 7:30 AM

-- March 31, 2026 --

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum Globe Newswire 7:30 AM

-- March 17, 2026 --

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs Globe Newswire 7:30 AM

-- March 10, 2026 --

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers Globe Newswire 5:30 AM
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology Business Wire 5:00 AM

-- February 3, 2026 --

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia Globe Newswire 9:30 PM
Market Data Delayed 15 Minutes